Physician profile
Jacob D Dewitt
NPI 1750878955
$4,752.77
in general payments reported to CMS, 2019-2025
24 companies · $495 in 2025
The $495 reported for 2025 was more than what 86% of Integrative Medicine providers received nationally (typical 2025 total: $57.65).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $195 · 2021: $209 · 2022: $1,238 · 2023: $752 · 2024: $1,864 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,025 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,025.31 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,232.03 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $703.23 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $599.36 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Paratek Pharmaceuticals, INC. | $562.60 | 2022-2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $320.40 | 2023-2025 | |
| Esperion Therapeutics, INC. | $207.11 | 2022-2024 | Nexletol |
| Glaxosmithkline, LLC. | $145.74 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $135.43 | 2023-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $118.21 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.93 | 2022-2023 | Xifaxan |
| Lilly USA, LLC | $82.88 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Idorsia Pharmaceuticals US INC | $58.76 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $33.12 | 2022 | |
| Ironshore Pharmaceuticals INC. | $31.64 | 2022-2024 | |
| Genentech USA, INC. | $30.23 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $28.90 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $17.16 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $16.21 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.69 | 2022 | |
| Itamar Medical INC | $14.25 | 2024 | Watchpatone |
| Pfizer INC. | $13.67 | 2023 | |
| Shield Therapeutics INC | $13.44 | 2023 | Accrufer |
| Amneal Pharmaceuticals LLC | $13.22 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.